Related references
Note: Only part of the references are listed.The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation
Stefan O. Ciurea et al.
BONE MARROW TRANSPLANTATION (2020)
The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation
Melhem M. Solh et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Peripheral blood stem cell for haploidentical transplantation with post-transplant high dose cyclophosphamide: detailed analysis of 181 consecutive patients
Angela Granata et al.
BONE MARROW TRANSPLANTATION (2019)
Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome
Thierry Guillaume et al.
BONE MARROW TRANSPLANTATION (2019)
Post-transplantation cyclophosphamide-based haploidentical versus Atg-based unrelated donor allogeneic stem cell transplantation for patients younger than 60 years with hematological malignancies: a single-center experience of 209 patients
Thomas Pagliardini et al.
BONE MARROW TRANSPLANTATION (2019)
Selecting the Best Donor for Haploidentical Transplant: Impact of HLA, Killer Cell Immunoglobulin-Like Receptor Genotyping, and Other Clinical Variables
Scott R. Solomon et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
CD3+graft cell count influence on chronic GVHD in haploidentical allogeneic transplantation using post-transplant cyclophosphamide
A. Mussetti et al.
BONE MARROW TRANSPLANTATION (2018)
Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report
Jakob R. Passweg et al.
BONE MARROW TRANSPLANTATION (2018)
Bone Marrow Versus Mobilized Peripheral Blood Stem Cells in Haploidentical Transplants Using Posttransplantation Cyclophosphamide
Annalisa Ruggeri et al.
CANCER (2018)
Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies
Arjun Datt Law et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Clofarabine-based reduced intensity conditioning regimen with peripheral blood stem cell graft and post-transplant cyclophosphamide in adults with myeloid malignancies
Patrice Chevallier et al.
Oncotarget (2018)
Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft-versus-host disease prophylaxis in haploidentical transplant
Annalisa Ruggeri et al.
HAEMATOLOGICA (2017)
Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft-versus-host disease prophylaxis in haploidentical transplant
Annalisa Ruggeri et al.
HAEMATOLOGICA (2017)
Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide
Asad Bashey et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Prevents Graft-versus Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors
Fabrizio Carnevale-Schianca et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission
A. Ruggeri et al.
BONE MARROW TRANSPLANTATION (2016)
Haploidentical T Cell-Replete Transplantation with Post-Transplantation Cyclophosphamide for Patients in or above the Sixth Decade of Age Compared with Allogeneic Hematopoietic Stem Cell Transplantation from an Human Leukocyte Antigen-Matched Related or Unrelated Donor
Didier Blaise et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Graft-versus-Host Disease Prophylaxis in Unrelated Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil
Ivan S. Moiseev et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Higher Early Monocyte and Total Lymphocyte Counts Are Associated with Better Overall Survival after Standard Total Body Irradiation, Cyclophosphamide, and Fludarabine Reduced-Intensity Conditioning Double Umbilical Cord Blood Allogeneic Stem Cell Transplantation in Adults
Amandine Le Bourgeois et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium
Andrew C. Harris et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation?
Ying-Jun Chang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
High CD3+and CD34+peripheral blood stem cell grafts content is associated with increased risk of graft-versus-host disease without beneficial effect on disease control after reduced-intensity conditioning allogeneic transplantation from matched unrelated donors for acute myeloid leukemia - an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Tomasz Czerw et al.
ONCOTARGET (2016)
Effect of Total Nucleated and CD34+ Cell Dose on Outcome after Allogeneic Hematopoietic Stem Cell Transplantation
Mats Remberger et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells
Nicoletta Cieri et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation
Philippe Armand et al.
BLOOD (2014)
Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
Siddhartha Jaiswal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Impact of lymphocyte and monocyte recovery on the outcomes of allogeneic hematopoietic SCT with fludarabine and melphalan conditioning
L. J. DeCook et al.
BONE MARROW TRANSPLANTATION (2013)
Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan, and antithymocyte globulins (FB2 regimen) reduced-intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo-SCT)
Amandine Le Bourgeois et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2013)
Peripheral Blood Lymphocyte and Monocyte Recovery and Survival in Acute Leukemia Postmyeloablative Allogeneic Hematopoietic Stem Cell Transplant
Mary D. Thoma et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2012)
HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide
Leo Luznik et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2008)
National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report
AH Filipovich et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2005)
Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation
JA Pérez-Simón et al.
BLOOD (2003)
Higher doses of CD34+peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation
M Mohty et al.
LEUKEMIA (2003)
Flow cytometric assessment of lymphocyte subsets, lymphoid progenitors, and hematopoietic stem cells in allogeneic stem cell grafts
K Theilgaard-Mönch et al.
BONE MARROW TRANSPLANTATION (2001)
Immunobiology of allogeneic peripheral blood mononuclear cells mobilized with granulocyte-colony stimulating factor
M Gyger et al.
BONE MARROW TRANSPLANTATION (2000)
Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: Considerations for the allogeneic transplantation therapy of leukemia and lymphoma
DH Fowler et al.
LEUKEMIA & LYMPHOMA (2000)
Share Paper
